Menu

#Cohance

1 post

Feed
1 of 1 post
Cohance Lifesciences: Can a recovery justify its valuation?
🖼️
0Read More

Cohance Lifesciences: Can a recovery justify its valuation?

The Indian Express·Rahul Rao·13 days ago
#2eZ6v03z

Cohance Lifesciences business numbers have been hard to stomach. FY26 revenue fell 13% and adjusted EBITDA nearly halved. Q1 FY27 revenue fell 23%, adjusted EBITDA margin dropped to 2.2%, and the company reported a net loss of Rs 45 crore.…

15s